samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CARMAT Announces the First Human Implant of its Total Artificial Heart in the United States

CARMAT

The implant was performed at Duke University Hospital, one of the largest U.S. cardiology centers


Paris, July 15, 2021 - 7 am CEST
CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS).

The implant procedure was performed by a team led by Dr. Jacob N. Schroder and Dr. Carmelo A. Milano, heart surgeons at Duke University Hospital, in Durham (North Carolina). Duke University Hospital is rated as one of the best in the United States for its outstanding care and ground-breaking research, especially in cardiology and heart surgery. It is the first U.S. hospital to implant Aeson® within the framework of the EFS. Three additional U.S. centers are fully trained and are currently screening patients for the study.


In accordance with the study protocol approved by the FDA, 10 transplant-eligible patients are expected to be enrolled in this trial. The primary study endpoint is patient survival at 180 days post-implant or a successful cardiac transplantation within 180 days post-implant. It is a staged study with a progress report of the first 3 patients after 60 days, before the enrollment of the next 7 patients.

Carmelo A. Milano, MD, heart surgeon at Duke University Hospital, and principal investigator of the study, stated: "We are pleased to be the first U.S. center to investigate a new therapeutic alternative for critically ill patients suffering from end-stage biventricular heart failure. This clinical study will help us determine whether the device's properties -- including hemocompatibility, pulsatility, autoregulation and silent operation -- are beneficial to patients who currently have very few options."

Stéphane Piat, Chief Executive Officer of CARMAT, concluded: "We are honored that our device is implanted at Duke University Hospital, which is recognized throughout the United States for its quality of care and research. I would like to congratulate the teams at the hospital, as well as our technical and medical staff, on this exceptional milestone for both patients and our company. I am also very pleased that, despite the procedures hardened by the Covid-19 situation, three other centers are now fully trained and ready to join our first U.S. clinical study that will be instrumental to our development in the world's largest medical device market."
phone +33(0)1 39 45 64 50
email contact@carmatsas.com
web www.carmatsa.com/en
email 36, avenue de l’Europe Immeuble l’Etendard 78140 Vélizy-Villacoubla
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement